UNASSIGNED: 2068 Background: Greater than 70% of @entity1 diagnosed with @entity2946 today are cured. However, salvage therapy after recurrence remains widely varied. Survival after recurrence of @entity2946 has not been reported in an unselected cohort of @entity1 in the contemporary era. METHODS: With approval of the Institutional Review Board, medical records were reviewed for 55 @entity1 diagnosed with @entity2946 between 2000 and 2010, and treated at Seattle @entity1 's Hospital, the largest pediatric @entity5 center in the Pacific Northwest, with referrals from Washington, Alaska, Montana, Idaho and Wyoming. Forty-seven @entity1 over the age of three at initial diagnosis were considered for this analysis. The following variables were collected for @entity1 diagnosed with recurrent or progressive disease: age at diagnosis, gender, stage, histology, time to relapse, site of relapse, treatment after relapse, and time to @entity204 or last contact. Survival was described according to the method of Kaplan and Meier and comparisons were made using the log rank test. RESULTS: Fourteen of 47 @entity1 (30%) experienced recurrent or progressive @entity2946 . The median age at diagnosis was 9 years (range 5.8 to 15.9), and 71% (n=10) were male. Most @entity1 had @entity66 (M0, 78.6%), classic histology (78.6%) and gross total resection (92.9%) at initial diagnosis. The median time from diagnosis to recurrence was 18.0 months (range 3.6 - 62.6), and site of recurrence was metastatic in 86% (n=12). The median survival after relapse was 6.8 months (range 0.7 - 77.9); 3-year survival after relapse was 19%. There were trend associations between longer survival and having received additional chemotherapy (median survival 6.8 vs. 1.3 months, p = 0.06) and radiation therapy (15.4 vs. 4.4 months, p=0.13), but not research therapy (2.8 vs. 10.3 months, p =0.69.) Conclusions: Recurrence of @entity2946 is much more likely to be metastatic than reported in previous eras. Within the limits of our small sample, our data suggest a potential survival benefit from re-treatment with cytotoxic chemotherapy and radiation even in heavily pre-treated @entity1 . This report serves as a baseline against which to evaluate novel therapy combinations.

Survival after recurrence of XXXX in the contemporary era.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children'] @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity2946 :: ('MESH:D008527', 'Disease') :: ['medulloblastoma']
@entity2946 :: (MESH:D008527,Disease) :: ['medulloblastoma']
